Atezolizumab, targeting PD-L1, showed promising efficacy in different trials, particularly in the first-line setting, improving OS in NSCLC patients with high PD-L1 expression, leading to FDA approvals after post-chemotherapy progression and as a first-line treatment in patients with high PD-L1 expression (49, 50). Here, CD274 is linked to non-small cell lung carcinoma.